Type 1 diabetes is an autoimmune disease that destroys insulin production by pancreatic islet cells, leading to a chronic and challenging-to-manage disease. With 40,000 new cases annually, type 1 diabetes affects more than 1.25 million Americans, with peak diagnosis in children between the ages of 2 and 17. Up to 40 percent of new cases are diagnosed with potentially life-threatening conditions such as diabetic ketoacidosis. Autoantibody markers appear well in advance of symptoms, and pilot studies have shown that screening for these markers can reduce the rates of often-deadly diabetic ketoacidosis at diagnosis, reduce medical complications and potentially improve patients’ quality of life.
About 80 percent of all children diagnosed with type 1 diabetes have no family history or known genetic predisposition. Stanford’s Division of Pediatric Endocrinology and Diabetes and Enable Biosciences are partnering with JDRF to validate and expand the capability of Enable Biosciences’ Antibody Detection by Agglutination-PCR (ADAP) assay platform for diagnosing type 1 diabetes.
Type 1 diabetes is an autoimmune disorder that affects 1-2 million Americans
40% of new cases are diagnosed with diabetic ketoacidosis, a potentially life-threatening condition
Autoantibodies signal years in advance of symptoms
Testing for autoantibodies can reduce rates of medical complications and potentially improve quality of life
Enable Biosciences is producing an improved autoantibody assay with JDRF and Stanford